1 option
Clinical review report Guselkumab (Tremfya) (Janssen Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Outcome assessment (Medical care)--Methodology.
- Physical Description:
- 1 online resource
- Edition:
- Version: final.
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- The objective of this review was to perform a systematic review of the beneficial and harmful effects of guselkumab 100 mg administered as a subcutaneous (SC) injection for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.